Form 4: UTHR COO Exercises Options, Sells Shares Under 10b5-1 Plan

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold 22,500 common shares as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), exercised stock options on February 2, 2026.
• A total of 14,625 options were exercised at a price of $117.76 per share.
• An additional 7,875 options were exercised at a price of $146.03 per share.
• Immediately following the exercise, Benkowitz sold all 22,500 resulting common shares at an average price of $470.9524 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• The shares were held in trusts where Benkowitz is a beneficiary and/or has investment and voting power.
• Following these transactions, Benkowitz directly owns 2,648 shares of Common Stock.
• Benkowitz also beneficially owns 38,625 stock options through one trust and 20,815 stock options through another trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, pre-planned insider transaction. While any insider sale can carry a slight negative sentiment, the execution under a Rule 10b5-1 plan mitigates strong negative interpretations, suggesting a neutral to slightly positive context due to the pre-planning.

Positives

• The significant difference between the option exercise prices ($117.76 and $146.03) and the sale price ($470.9524) indicates a substantial gain for the reporting person.
• The transaction was executed under a Rule 10b5-1 trading plan, suggesting a pre-scheduled liquidity event rather than a reactive sale based on new, potentially negative, information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the 10b5-1 plan mitigates this interpretation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals about management's confidence. However, sales under a Rule 10b5-1 plan are generally viewed as less indicative of a negative outlook compared to unplanned sales, as they are pre-scheduled to avoid accusations of trading on material non-public information. This transaction is a routine part of executive compensation and liquidity management.

Related Party Transactions

• The transactions involved shares held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees with shared investment and voting power.
• Additional transactions involved shares held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.

Stakeholder Impact

• Shareholders may view the insider sale with slight caution, but the pre-arranged nature via a 10b5-1 plan typically reduces concerns about management's immediate outlook on the company's prospects.

Key Dates

Recommendation

The filing details a pre-planned insider sale of shares by a key executive. While insider selling can sometimes be a bearish signal, the execution under a Rule 10b5-1 plan suggests a pre-determined liquidity event rather than a reaction to new, negative information. The transaction itself does not provide new fundamental information about the company's operations or future prospects to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future company developments.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale, Michael Benkowitz